Abstract Library

#4469 Therapeutic strategy for pancreatic neuroendocrine tumours: An overview of the TNE West Network (2016-2024)

Introduction: Neuroendocrine tumours (NETs) are relatively rare and often diagnosed at an advanced stage, typically occurring between the ages of 40 and 60. They primarily manifest in the gastrointestinal system, pancreas, bronchi, lungs, thymus, and thyroid.

Conference:

Presenting Author: Bengueddach A

Authors: Bengueddache A, Kehili H, Tidjane A, Tabeti B, Manouni C,

Keywords: neuroendocrine tumour, metastasis, somatostatin analogue, pancreas,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,

#4245 Carcinoid heart in neuroendcrine tumor – Experience of medical departement oncology Oran, Algeria

Introduction: The carcinoid heart is present in approximately 20% of cases at the diagnosis of carcinoid dyndrome in neuroendocrine tumors, and will occur in approximately 50% of patients during follow-up. The consequence is the appearance of stenosing and/or leaking valvular diseases, responsible, eventually, right or left ventricular dysfunction and severe heart failure. Only surgical valve replacement treatment seems to be able to improve the prognosis, but at the cost of significant perioperative morbidity and mortality.

Conference:

Presenting Author: Kaid M

Authors: Kaid M, Bengueddach A, Bennaoum A, Kehili H, Bereksi-Reguig F,

Keywords: carcinoid heart disease, somatostatin,

#3945 8-year follow-up reveals therapeutic approaches for patients with neuroendocrine neoplasms – Findings from the TNE West Network: 2016-2023

Introduction: Neuroendocrine tumors (NETs) are relatively rare and often diagnosed late, typically occurring between the ages of 40 and 60. They primarily manifest in the gastrointestinal system, pancreas, bronchi, lungs, thymus, and thyroid.

Conference:

Presenting Author:

Authors: Bengueddach A, Kehili H, Tidjane A, Benaoum A, Khalifa S,

Keywords: neuroendocrine tumor, metastasis, somatostatin analogues,

#3773 Pancreatic neuroendocrine tumors in Oran – Epidemiological, histological and therapeutic aspects

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, they represent third of digestive NETs. Their incidence is increasing with a rate that has been multiplied by 5 over the past 20 years to reach 0.6 cases/100,000. This increase is probably related to better detection of this type of tumor. The discovery is often fortuitous or following a non-specific symptomatology which depends on the seat of the tumor. They are often the cause of mainly hepatic metastases. Only surgery at an early stage allows a good evolution. Few data are available on pNETs in our country.

Conference:

Presenting Author:

Authors: Boumansour N, Khalifa S, Kehili H, Bengueddache A, Tabeti B,

Keywords: pancreas, neuroendocrine tumor, epidemiology, histology,